The integration into Roche’s navify platform is expected maximise access to Lunit’s AI-powered biomarker. Credit: Lunit.

Lunit has collaborated with Roche to improve precision medicine and improve cancer biomarker testing.

Luni’s AI-powered tool, Lunit SCOPE PD-L1 22C3 TPS, is integrated into Roche’s navify Digital Pathology platform.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This partnership represents the first deployment of Lunit’s AI technology with Roche, aiming to provide pathologists and scientists with advanced tools for cancer research and diagnostics.

Roche’s navify Digital Pathology now features a suite of AI-driven algorithms, including Lunit SCOPE.

This integration facilitates access to external innovations and aims to improve biomarker testing for cancer research, potentially leading to better patient outcomes through precision medicine.

See Also:

The collaboration has a broad geographic reach, initially launching in the US and planning future expansions to Canada, the European Union (including the UK), South Korea, and Japan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The strategic move is designed to enhance cancer diagnostics and treatment across various healthcare markets worldwide.

The Lunit SCOPE PD-L1 22C3 TPS leverages AI to provide valuable insights and analysis of the PD-L1 tumour proportion score (TPS), an essential biomarker in cancer immunotherapy.

By automating the PD-L1 scoring process, the AI tool offers more consistent, accurate, and efficient assessments, which is particularly beneficial for a challenging biomarker such as PD-L1 TPS.

 Since 2021, Lunit SCOPE PD-L1 has been available for research use only.

Lunit said the integration into Roche’s navify platform will maximise access to this AI technology.

Lunit CEO Brandon Suh said: “We’re thrilled to work together with Roche within its open digital pathology ecosystem, which we believe will create powerful synergies and represent a significant step toward making Lunit’s AI tools accessible globally.

“Today, we have made PD-L1 analysis available, and we look forward to sharing more of our tools on this platform in the future. By integrating our precise and reliable algorithms, we aim to accelerate the advancement of precision medicine, enhancing workflow efficiency and introducing new biomarkers for improved patient care.”

In December 2023, Lunit agreed to acquire Volpara Health Technologies in a deal valued A$292m ($193m).